कृपया अन्य खोज का प्रयास करें
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Somasundaram Subramaniam | 70 | 2018 | Independent Director |
Raju S. Mohan | 67 | 2018 | Founder, CEO, President & Director |
William R. White | 51 | 2021 | Independent Director |
Sheila K. Gujrathi | 54 | 2021 | Executive Chairperson |
Emma Guttman-Yassky | - | - | Member of Clinical & Scientific Advisory Board |
Bruce E. Sands | - | - | Member of Clinical & Scientific Advisory Board |
James G. Krueger | - | - | Member of Clinical & Scientific Advisory Board |
Luisa Salter-Cid | 60 | 2021 | Member of Advisory Board |
Allison J. Hulme | 61 | 2023 | Independent Director |
Alexa Boer Kimball | - | - | Member of Clinical & Scientific Advisory Board |
Onaiza Cadoret-Manier | 60 | 2023 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है